SG11202000224SA - An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof - Google Patents

An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof

Info

Publication number
SG11202000224SA
SG11202000224SA SG11202000224SA SG11202000224SA SG11202000224SA SG 11202000224S A SG11202000224S A SG 11202000224SA SG 11202000224S A SG11202000224S A SG 11202000224SA SG 11202000224S A SG11202000224S A SG 11202000224SA SG 11202000224S A SG11202000224S A SG 11202000224SA
Authority
SG
Singapore
Prior art keywords
preparation
immunogenic composition
improved stability
enhanced immunogenicity
reduced reactogenicity
Prior art date
Application number
SG11202000224SA
Other languages
English (en)
Inventor
Kumar Rakesh
Inder Jit Sharma
Anil Vyankatrao Shitole
Manohar Doddapaneni
Hitt Jyoti Sharma
Original Assignee
Serum Inst Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Inst Of India Pvt Ltd filed Critical Serum Inst Of India Pvt Ltd
Publication of SG11202000224SA publication Critical patent/SG11202000224SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0016Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/05Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SG11202000224SA 2017-07-18 2018-07-13 An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof SG11202000224SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721025513 2017-07-18
PCT/IB2018/055180 WO2019016654A1 (en) 2017-07-18 2018-07-13 IMMUNOGENIC COMPOSITION WITH IMPROVED STABILITY, ENHANCED IMMUNOGENICITY, AND LESS REACTOGENICITY, AND PREPARATION METHOD THEREOF

Publications (1)

Publication Number Publication Date
SG11202000224SA true SG11202000224SA (en) 2020-02-27

Family

ID=63556364

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000224SA SG11202000224SA (en) 2017-07-18 2018-07-13 An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof

Country Status (21)

Country Link
US (1) US11179453B2 (https=)
EP (1) EP3655024A1 (https=)
JP (1) JP7404226B2 (https=)
KR (1) KR102657910B1 (https=)
CN (1) CN111032078A (https=)
AU (1) AU2018302767B2 (https=)
BR (1) BR112020000999A2 (https=)
CA (1) CA3070039A1 (https=)
CO (1) CO2020001765A2 (https=)
EA (1) EA202090316A1 (https=)
GE (2) GEP20227386B (https=)
JO (1) JOP20180069B1 (https=)
MX (1) MX2020000441A (https=)
PE (1) PE20201443A1 (https=)
PH (1) PH12020500133A1 (https=)
SG (1) SG11202000224SA (https=)
TW (1) TWI786153B (https=)
UA (1) UA128204C2 (https=)
UY (1) UY37811A (https=)
WO (1) WO2019016654A1 (https=)
ZA (1) ZA202000889B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8398983B2 (en) * 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
EP3800244A1 (en) 2006-03-10 2021-04-07 Institut Pasteur de Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
CA2759280C (en) 2009-04-28 2016-09-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
CA3077428A1 (en) * 2017-10-18 2019-04-25 Institut Pasteur De Lille Bordetella strains expressing serotype 3 fimbriae
MX2021004233A (es) * 2018-10-12 2021-08-16 Serum Inst Of India Private Ltd Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma.
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
CN112138155B (zh) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 一种复合佐剂系统及制备该佐剂的方法
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
EP3988289A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method of manufacturing a spectacle lens
EP3988290A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method for manufacturing a spectacle lens
EP3988288A1 (en) 2020-10-23 2022-04-27 Carl Zeiss Vision International GmbH Method of manufacturing a spectacle lens
WO2022114921A1 (ko) * 2020-11-30 2022-06-02 주식회사 엘지화학 알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법
JP7526880B2 (ja) * 2021-04-20 2024-08-01 Kmバイオロジクス株式会社 6種混合液状ワクチン組成物
CN120826235A (zh) * 2023-03-16 2025-10-21 艾芬尼维克斯公司 免疫原性组合物
CN119799602A (zh) * 2025-03-17 2025-04-11 艾美坚持生物制药有限公司 一种破伤风梭状芽胞杆菌发酵培养基及培养方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI945483A7 (fi) 1992-05-23 1995-01-20 Smithkline Beecham Biologicals S A Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
CA2303105A1 (en) 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
EP1004314A1 (fr) 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0616226D0 (en) 2006-08-15 2006-09-27 Novartis Ag Processes
US8945582B2 (en) * 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
EP3459562B1 (en) * 2011-01-05 2024-03-20 Bharat Biotech International Limited A combination heptavalent vaccine
AU2014304545A1 (en) * 2013-08-05 2016-02-25 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
EA037283B1 (ru) * 2015-09-16 2021-03-04 ЭлДжи КЕМ, ЛТД. Комбинированная вакцинная композиция для многократного дозирования

Also Published As

Publication number Publication date
EA202090316A1 (ru) 2020-12-08
KR20200042470A (ko) 2020-04-23
MX2020000441A (es) 2020-08-17
JP7404226B2 (ja) 2023-12-25
WO2019016654A1 (en) 2019-01-24
US11179453B2 (en) 2021-11-23
UY37811A (es) 2019-01-02
GEP20227386B (en) 2022-06-10
EP3655024A1 (en) 2020-05-27
AU2018302767A1 (en) 2020-03-05
CN111032078A (zh) 2020-04-17
TW201919690A (zh) 2019-06-01
GEAP202115276A (en) 2021-12-27
PH12020500133A1 (en) 2021-02-08
CA3070039A1 (en) 2019-01-24
KR102657910B1 (ko) 2024-04-18
US20200206331A1 (en) 2020-07-02
CO2020001765A2 (es) 2020-05-29
UA128204C2 (uk) 2024-05-08
PE20201443A1 (es) 2020-12-10
TWI786153B (zh) 2022-12-11
JOP20180069A1 (ar) 2019-01-18
JP2020527571A (ja) 2020-09-10
ZA202000889B (en) 2021-06-30
BR112020000999A2 (pt) 2020-07-14
JOP20180069B1 (ar) 2022-09-15
AU2018302767B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
ZA202000889B (en) An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
IL257800A (en) Immune compositions with improved stability and immunogenicity
HK1253271A1 (zh) 用於瘤形成疫苗的配制品及其制备方法
IL268168A (en) Immunogenic preparations for use as a vaccine against pneumococcus
ZA201807203B (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
SG11202001161YA (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
IL252915A0 (en) Immunogenic preparations for use in pneumococcal vaccines
SG11202003800YA (en) Zika vaccines and immunogenic compositions, and methods of using the same
LT3585803T (lt) Pneumokokinio konjugato vakcinos farmacinės formos
GB201814362D0 (en) Composition and process for preparing vaccine
HK1254344A1 (zh) 抗原匹配的流感疫苗
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
GB201711635D0 (en) Immunogenic composition
GB201610599D0 (en) Immunogenic Composition
IL271603A (en) Immunogenic preparations
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
GB201802339D0 (en) Immunogenic composition
EP3397277C0 (en) IMMUNOGENIC COMPOSITION
ZA201706867B (en) Bordetella pertussis immunogenic vaccine compositions
GB201711637D0 (en) Immunogenic composition
EP3270897A4 (en) Immunogenic compositions for use in vaccination against bordetella
GB2570806B (en) Immunogenic agent and associated compositions, uses and methods
GB201604755D0 (en) Immunogenic compositions
GB201803692D0 (en) Immunogenic composition
EP3271023A4 (en) Immunogenic compositions and vaccines for preventing or treating filarial disease